2013 Multimodality AUC

2013 Комплексное AUC для стабильной ИБС

This free app will help guide you through the process of reviewing appropriate use ratings for 7 cardiac imaging modalities for 80 clinical scenarios. This helpful tool is based on the ACCF/AHA/ASE/ASNC/HFSA/HRS/SCAI/SCCT/SCMR/STS 2013 Multimodality Appropriate Use Criteria for the Detection and Risk Assessment of Stable Ischemic Heart Disease.

Repurposed by permission from Elsevier Inc.: Wolk MJ, et al. J Am Coll Cardiol 2013 Dec 10.

Adapted from the report by the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, Society for Cardiovascular Magnetic Resonance, and Society of Thoracic Surgeons.

The material provided herein is for informational purposes only and is not intended to diagnose, treat, or prevent any disease or condition. Nothing herein should be construed as medical, legal, or other professional advice or opinion.

This application is intended to help guide healthcare professionals through the process of determining which cardiac imaging modalities are potentially appropriate for patients. By reviewing information about your patients through this application, you may determine which cardiac imaging modalities are considered appropriate, may be appropriate, or rarely appropriate for a given patient indication, based on the AUC developed by the authors of the publication listed above. Although these criteria may provide guidance, they are not intended to serve as substitutes for sound clinical judgment and practice experience.

Some authors of the publication on which this app is based have a financial relationship with Astellas. Financial compensation from Astellas was not received in relation to the creation of the 2013 Multimodality AUC publication.

012-0231-PM

© 2014 Astellas Pharma US, Inc.